Observations from the OMERACT Drug Safety Summit, May 2008.
Level V
Where this comes from
- Record sourced from PubMed, PMID 19738222.
- Also identified by DOI 10.3899/jrheum.090590.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Due to mounting concern about determination of benefit and risk in the context of product development and clinical practice the OMERACT Executive identified the need to bring together a variety of specialists to define risk. At the Drug Safety Summit held at OMERACT 9, specialists spoke on their given topics and the group considered risk in the context of formally posed questions.
Medical subject headings
- Antirheumatic Agents
- Drug-Related Side Effects and Adverse Reactions
- Rheumatic Diseases